1. High mobility group box-1 and diabetes mellitus complications: State of the art and future perspectives
- Author
-
Federico Biscetti, Maria Margherita Rando, Andrea Leonardo Cecchini, Elisabetta Nardella, Giovanni Pecorini, Raffaele Landolfi, and Andrea Flex
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Ischemia ,Review ,030204 cardiovascular system & hematology ,HMGB1 ,Models, Biological ,Catalysis ,Inorganic Chemistry ,Sepsis ,Diabetes Complications ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Models ,medicine ,Animals ,Humans ,Physical and Theoretical Chemistry ,HMGB1 Protein ,Intensive care medicine ,Molecular Biology ,Pathological ,High Mobility Group Box-1 (HMGB1) ,Spectroscopy ,Endemic disease ,biology ,business.industry ,Organic Chemistry ,Settore MED/09 - MEDICINA INTERNA ,Vascular complications ,General Medicine ,medicine.disease ,Biological ,3. Good health ,Computer Science Applications ,030104 developmental biology ,biology.protein ,business ,Diabetes Mellitus Complications - Abstract
Diabetes mellitus (DM) is an endemic disease, with growing health and social costs. The complications of diabetes can affect potentially all parts of the human body, from the heart to the kidneys, peripheral and central nervous system, and the vascular bed. Although many mechanisms have been studied, not all players responsible for these complications have been defined yet. High Mobility Group Box-1 (HMGB1) is a non-histone nuclear protein that has been implicated in many pathological processes, from sepsis to ischemia. The purpose of this review is to take stock of all the most recent data available on the role of HMGB1 in the complications of DM.
- Published
- 2019